Emerging Technologies for Assessing HER2 Amplification

Authors:

Abstract
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment o

This publication has 60 references indexed in Scilit: